ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021
04 Novembre 2021 - 6:45PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a next-generation biotech company dedicated to
the discovery and development of innovative therapies, announces
today its gross cash position as of September 30, 2021 and reviews
the highlights of the third quarter 2021.
Cash position
Cash and cash equivalents amounted to €3.2 million at September
30, 2021, compared to €4.8 million at June 30, 2021. This variation
is explained by the production of its bioproduct CER-001 and
continuing of R&D expenses, particularly in ophthalmology.
Highlights and outlook
Following the positive clinical results which led to the
disappearance of visual blur related to corneal deposits in a
patient suffering from LCAT deficiency, treated within the
framework of a Temporary Use Authorization, and to clear
improvement of the patient's visual functions, ABIONYX Pharma has
communicated initial positive preclinical results that indicate the
major therapeutic potential of bio-HDL in ophthalmology, and more
broadly the role of lipids in ocular pathologies.
By obtaining an orphan drug designation for CER-001, which
covers both a renal and an ophthalmological indication, ABIONYX
Pharma believes that the development of bio-HDL in ophthalmology
can be accelerated and is launching a strategic development of the
first class of biomedicines in ophthalmology based on its
bio-HDL.
In this context, ABIONYX Pharma has announced that it has
initiated discussions with IRIS Pharma, one of the world leaders in
preclinical and clinical research in ophthalmology under contract,
with a view to a possible strategic deal, with IRIS Pharma's
contract research activity intended to remain separate from the
biotech activity and to continue to grow. Given the quality of the
discussions, the company plans to communicate shortly on the terms
of this deal.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211104006095/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024